Oncological management of pancreatic cancer in advanced stages

D. Laheru

doi:10.1007/978-3-540-28656-1_55

Oncological management of pancreatic cancer in advanced stages

D. Laheru

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Historically, 5-fluorouracil (5-FU)-based chemotherapy has been the most widely studied chemotherapeutic agent for all stages of pancreatic cancer. Despite more recent attempts to modify the delivery of 5-FU, response rates have remained unchanged in the 10-20% range with median survival of 4-5 months for patients with stage IV disease [1-5].

Original language	English (US)
Title of host publication	Diseases of the Pancreas
Subtitle of host publication	Current Surgical Therapy
Publisher	Springer Berlin Heidelberg
Pages	549-557
Number of pages	9
ISBN (Print)	9783540286554
DOIs	https://doi.org/10.1007/978-3-540-28656-1_55
State	Published - Dec 1 2008

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-540-28656-1_55

Cite this

@inbook{5dc037741dd640969a23d0041e53f456,

title = "Oncological management of pancreatic cancer in advanced stages",

abstract = "Historically, 5-fluorouracil (5-FU)-based chemotherapy has been the most widely studied chemotherapeutic agent for all stages of pancreatic cancer. Despite more recent attempts to modify the delivery of 5-FU, response rates have remained unchanged in the 10-20% range with median survival of 4-5 months for patients with stage IV disease [1-5].",

author = "D. Laheru",

year = "2008",

month = dec,

day = "1",

doi = "10.1007/978-3-540-28656-1_55",

language = "English (US)",

isbn = "9783540286554",

pages = "549--557",

booktitle = "Diseases of the Pancreas",

publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Oncological management of pancreatic cancer in advanced stages

AU - Laheru, D.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Historically, 5-fluorouracil (5-FU)-based chemotherapy has been the most widely studied chemotherapeutic agent for all stages of pancreatic cancer. Despite more recent attempts to modify the delivery of 5-FU, response rates have remained unchanged in the 10-20% range with median survival of 4-5 months for patients with stage IV disease [1-5].

AB - Historically, 5-fluorouracil (5-FU)-based chemotherapy has been the most widely studied chemotherapeutic agent for all stages of pancreatic cancer. Despite more recent attempts to modify the delivery of 5-FU, response rates have remained unchanged in the 10-20% range with median survival of 4-5 months for patients with stage IV disease [1-5].

UR - http://www.scopus.com/inward/record.url?scp=84895288988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895288988&partnerID=8YFLogxK

U2 - 10.1007/978-3-540-28656-1_55

DO - 10.1007/978-3-540-28656-1_55

M3 - Chapter

AN - SCOPUS:84895288988

SN - 9783540286554

SP - 549

EP - 557

BT - Diseases of the Pancreas

PB - Springer Berlin Heidelberg

ER -

Oncological management of pancreatic cancer in advanced stages

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this